Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Dynamk Capital
BioCentury | Dec 21, 2023
Finance
Dec. 20 Quick Takes: CNS and topical TYK2 inhibitor company Sudo raises $116M series B
Plus: Dynamk’s Kranjac launches new equity firm, PureTech reveals newcos and updates from bluebird, Calliditas and Merck
BioCentury | Oct 1, 2021
Finance
Sept. 30 Quick Takes: Advent closes €86M second fund
Data for Sanofi’s anti-OX40 mAb, plus TrialSpark’s $156M series C, Minerva’s next step toward schizophrenia submission and more
BioCentury | Apr 29, 2021
Product Development
April 28 Quick Takes: Brukinsa data buoy BeiGene; plus Adverum, Dynamk, Pfizer-Amplyx, Boundless Bio and Clarus
Positive Phase III data for Brukinsa zanubrutinib lifted shares of BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) 9% on NASDAQ, leaving the company with a market cap of $32 billion. The Btk inhibitor showed
BioCentury | Mar 19, 2021
Deals
March 18 Quick Takes: SPAC Revolution, Idera, Translate tumble; plus Anima-Takeda, Boston-GSK, Accelmed, Gain IPO and more
$500M IPO for SPAC backed by Arch, General Catalyst, LeidenBlank-check company Revolution Healthcare Acquisition Corp. (NASDAQ:REVHU) raised $500 million in an initial public offering through the sale
BioCentury | Oct 6, 2020
Deals
Oct. 5 Quick Takes: BridgeBio reacquiring Eidos, Amgen KRAS data, after-hours tumbles for Iovance, Y-mAbs and more
BridgeBio reacquiring Eidos spinoutFour years after spinning out Eidos Therapeutics Inc. (NASDAQ:EIDX), BridgeBio Pharma Inc. (NASDAQ:BBIO) will acquire the 36.3% of that company it does not already
BioCentury | Apr 10, 2020
Management Tracks
Shakeup at Arix; plus Emergent, AlloVir, Asklepios Bio, Morphic, Gritstone and more
BioCentury | Apr 1, 2020
Finance
March 31 Quick Takes: Cowen leads €47M addition to AM-Pharma's C round; plus Zucara, CellFe, Zentalis and Shanghai Junshi
BioCentury | Jan 30, 2020
Financial News
Jan. 29 Financial Quick Takes: Black Diamond prices upsized IPO; plus Biohaven, Denali, Concert follow-ons, Lyra, Annovis, Histogen-Conatus and CellFE
BioCentury | Aug 14, 2019
Financial News
Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more
BioCentury | May 30, 2019
Company News
Management tracks: Sanofi hires Atara's Berger; plus Emmaus, enGene and more
Items per page:
1 - 10 of 13